Allianz Asset Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Allianz Asset Management’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-63,744	Closed	-$1.28M	–	2742
2018 Q3	$1.28M	Buy	63,744 +8,507	+15%	+$200K	﹤0.01%	2121
2018 Q2	$1.43M	Sell	55,237 -357	-0.6%	-$9.88K	﹤0.01%	2089
2018 Q1	$1.33M	Buy	55,594 +2,513	+5%	+$79.2K	﹤0.01%	2096
2017 Q4	$1.8M	Sell	53,081 -929	-2%	-$25.9K	﹤0.01%	2054
2017 Q3	$1.14M	Sell	54,010 -331	-0.6%	-$6.07K	﹤0.01%	2199
2017 Q2	$950K	Sell	54,341 -1,139	-2%	-$18.8K	﹤0.01%	2239
2017 Q1	$971K	Buy	55,480 +30,952	+126%	+$527K	﹤0.01%	2247
2016 Q4	$415K	Sell	24,528 -6,031	-20%	-$93.3K	﹤0.01%	2404
2016 Q3	$501K	Sell	30,559 -5,917	-16%	-$89.9K	﹤0.01%	2358
2016 Q2	$552K	Buy	+36,476	New	+$601K	﹤0.01%	2289

Other funds holding ADMS

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Allianz Asset Management's ADMS Position: Q4 2018 in Review

Allianz Asset Management sold out of Adamas Pharmaceuticals (ADMS) in Q4 2018, closing a stake of 63,744 shares — an estimated $1.28M sold.

Allianz Asset Management first reported a position in ADMS in Q2 2016 and held it in 10 quarters. The position peaked at $1.8M in Q4 2017. 98 funds tracked by Wall St. Rank hold ADMS as of Q4 2018.

Allianz Asset Management reported no remaining Adamas Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Allianz Asset Management sold 63,744 Adamas Pharmaceuticals shares in Q4 2018, an estimated $1.28M.
Allianz Asset Management first reported a position in Adamas Pharmaceuticals in Q2 2016 and held it in 10 quarters.
Allianz Asset Management's Adamas Pharmaceuticals position peaked at $1.8M in Q4 2017.
98 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2018.

Based on Allianz Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.